ABSTRACT Purpose: Patients with unresectable/metastatic chondrosarcoma have poor prognoses; conventional chondrosarcoma is associated with a median progression-free survival (PFS) of <4 months after first-line chemotherapy. No standard targeted…

By Elizabeth Goldstein-Rice Prepare. Communicate. Find Support. Read our Comprehensive Guide for the Newly Diagnosed There are numerous and important reasons why someone who has been diagnosed with sarcoma should be treated at a center where…

ANN ARBOR, MI May 9, 2023 – SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce that it has launched a national, virtual multidisciplinary sarcoma tumor board. As the care of patients with cancer, particularly uncommon…

Podcast: From Physician to Patient Dan Hurley, M.D. Dan Hurley, M.D. is an otolaryngologist (Ear, Nose, Throat) residing in Arizona. He was diagnosed with dediffereniated chondrosarcoma, a rare form of bone cancer. While he was preparing to receive…

This coming Monday, May 22, we are going to do our first analysis of responses to the survey and take a first look at identifying trends and cause-effect relationships. Your responses to the survey questions are vital to this effort. We want to…

During the past three years many CS Patients, caregivers, family members and friends have supported the Foundation through their donations and fund-raising activities. We received donations from family members in honor of their lost loved ones to…

BOWIE, Maryland, May 12—The Chondrosarcoma (CS) Foundation will commemorate its third anniversary by continuing to educate the public about this rare bone cancer, advocate for patients fighting the disease and conduct a global natural history…

The Chondrosarcoma Foundation in partnership with NORD® launched the Chondrosarcoma Patient Registry on March 1, 2023. The Chondrosarcoma Patient Registry is a platform for patients around the world to strengthen their voices and collectively share…